FDA Approves Wezlana for Multiple Inflammatory Diseases
THURSDAY, Nov. 2, 2023 -- The U.S. Food and Drug Administration has approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases.
The approval includes indications... (Source: Drugs.com - Pharma News)
Source: Drugs.com - Pharma News - November 2, 2023 Category: Pharmaceuticals Source Type: news
FDA Approves First Ustekinumab Biosimilar FDA Approves First Ustekinumab Biosimilar
The drug has also been granted an interchangeability designation and has been approved for six indications.Medscape Medical News (Source: Medscape Allergy Headlines)
Source: Medscape Allergy Headlines - November 1, 2023 Category: Allergy & Immunology Tags: Rheumatology News Alert Source Type: news
Stelara Biosimilar OK'd With Interchangeability
(MedPage Today) -- A biosimilar version of the multipurpose biologic drug ustekinumab has been approved by the FDA and can be swapped interchangeably with the original product sold as Stelara.
The new version carries the brand name Wezlana and... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - November 1, 2023 Category: American Health Source Type: news
Amgen cleared in U.S. to market biosimilar to J & J ’s Stelara
(Source: Reuters: Health)
Source: Reuters: Health - November 1, 2023 Category: Consumer Health News Source Type: news
FDA Approves Wezlana (ustekinumab-auub), an Interchangeable Biosimilar to Stelara
October 31, 2023 -- Today, the U.S. Food and Drug Administration approved Wezlana (ustekinumab-auub) as a biosimilar to and interchangeable with Stelara (ustekinumab) for multiple inflammatory diseases. Wezlana, like Stelara, is approved to treat... (Source: Drugs.com - New Drug Approvals)
Source: Drugs.com - New Drug Approvals - October 31, 2023 Category: Drugs & Pharmacology Source Type: news
FDA Approves Interchangeable Biosimilar for Multiple Inflammatory Diseases
The FDA approved Wezlana, an interchangeable biosimilar to Stelara for multiple inflammatory diseases. (Source: FDA Center for Drug Evaluation and Research - What's New)
Source: FDA Center for Drug Evaluation and Research - What's New - October 31, 2023 Category: Drugs & Pharmacology Authors: FDA Source Type: news
J & J raises annual profit forecast on strong demand for top-selling anti-inflammatory drug
Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its top-selling drug Stelara and recorded a $21 billion gain from the spin off of its consumer health unit. The company's shares were up about 2% in premarket trading. Investors are focused on how Johnson…#johnsonjohnson #stelara (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2023 Category: Consumer Health News Source Type: news
J & J raises annual profit forecast on anti-inflammatory drug demand
Johnson & Johnson on Tuesday raised its 2023 profit forecast, helped by resilient demand for its anti-inflammatory drug Stelara and recorded a $21 billion gain from the spin off of its consumer health unit. Investors are focused on how Johnson & Johnson, now a standalone pharmaceutical and medical…#johnsonjohnson (Source: Reuters: Health)
Source: Reuters: Health - October 17, 2023 Category: Consumer Health News Source Type: news
Remission Doubled With Risankizumab vs Ustekinumab in CD Remission Doubled With Risankizumab vs Ustekinumab in CD
Phase 3b results show risankizumab is superior for endoscopic remission and clinical remission at week 48 compared with ustekinumab, a"once in a career" result, study authors say.Medscape Medical News (Source: Medscape Gastroenterology Headlines)
Source: Medscape Gastroenterology Headlines - October 16, 2023 Category: Gastroenterology Tags: Gastroenterology News Source Type: news
A 'SAD' Story: Patient Stuck With $176K Bill After Medicare Policy Switch
(MedPage Today) -- For 5 years, retiree George Beitzel went to a Sacramento-area clinic every 2 months so a nurse could give him an injection of the costly drug ustekinumab (Stelara), which his doctors prescribed for his Crohn's disease.
To have... (Source: MedPage Today Public Health)
Source: MedPage Today Public Health - September 14, 2023 Category: American Health Source Type: news
BioFactura, Inc. publishes Phase 1 data on its Ustekinumab biosimilar
BioFactura, Inc. announced the publication of the phase 1 study for BFI-751, a biosimilar candidate to Stelara (ustekinumab) in the peer reviewed journal, Clinical Pharmacology in Drug Development FREDERICK, Md., Sept. 11, 2023 /PRNewswire-PRWeb/ -- BioFactura, Inc. announced the... (Source: PRWeb: Medical Pharmaceuticals)
Source: PRWeb: Medical Pharmaceuticals - September 11, 2023 Category: Pharmaceuticals Tags: TRI Source Type: news
The 10 Drugs Medicare Can Negotiate Were Just Announced. These Pharma Stocks Are Impacted
Eliquis, Jardiance, and Stelara are among the first of 10 different drugs that are now subject to Medicare price negotiations following the passing of the Inflation Reduction Act.#medicare (Source: Reuters: Health)
Source: Reuters: Health - August 29, 2023 Category: Consumer Health News Source Type: news
Improvements After 3-Year Ustekinumab or TNFi PsA Treatment Improvements After 3-Year Ustekinumab or TNFi PsA Treatment
Did these therapies lead to outcome and productivity improvements among psoriatic arthritis patients? A new study evaluated the real-world effects.Arthritis Research & Therapy (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2023 Category: Consumer Health News Tags: Rheumatology Journal Article Source Type: news
Biologics After Exposure to TNF Inhibitors in Ulcerative Colitis Biologics After Exposure to TNF Inhibitors in Ulcerative Colitis
This study assessed the real-world efficacy of vedolizumab, ustekinumab and tofacitinib as second-line therapies in patients with ulcerative colitis who were previously exposed to a TNF inhibitor.Alimentary Pharmacology & Therapeutics (Source: Medscape Today Headlines)
Source: Medscape Today Headlines - August 8, 2023 Category: Consumer Health News Tags: Gastroenterology Journal Article Source Type: news
Aurobindo Pharma subsidiary enters pact with BioFactura for biosimilar ustekinumab
CuraTeQ Biologics, a wholly owned subsidiary of Aurobindo Pharma said it has entered into an exclusive license agreement with the US-based BioFactura to commercialize BFI-751, a proposed biosimilar to Stelara (ustekinumab). Ustekinumab is used for treating Crohn's disease, ulcerative colitis, plaque psoriasis and psoriatic arthritis. (Source: The Economic Times Healthcare and Biotech News)
Source: The Economic Times Healthcare and Biotech News - July 10, 2023 Category: Pharmaceuticals Source Type: news
